JAK2V617F-iPSCs did not exhibit a significant increase in erythroid cell proliferation or differentiation, most likely because the studied JAK2V617F expression was more consistent with the heterozygous JAK2V617F mutation in ET patients, where the endogenous JAK2 gene was still present [148,149]. Here, JAK2 is linked to essential thrombocythemia.